Aspirin-induced asthma (Q42859): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Em alguns indivíduos com asma, ácido acetilsalicílico (aspirina®) ou outros anti-inflamatórios não esterodais (AINEs), que bloqueiam a cicloxigenase 1 (COX-1), podem exacerbar a condição. Essa síndrome clínica distinta, chamada asma induzida por aspirina (AIA), é caracterizada por rinossinusite eosinofílica, polipose nasal, hipersensibilidade à aspirina e asma. | |||||||||||||||
| description / en | description / en | ||||||||||||||
In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1030818265 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:CA23.20 | |||||||||||||||
| Property / CURIE: CID11:CA23.20 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-CA23.20 | |||||||||||||||
| Property / Canary Token: dki-india-CA23.20 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: J45 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 09:35, 13 August 2026
In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | CA23.20 |
||
| English | Aspirin-induced asthma |
In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma. |
Statements
CID11:CA23.20
0 references
dki-india-CA23.20
0 references
Concluído
0 references
13 August 2026
0 references
